Quoin Pharmaceuticals (QNRX) has launched the “NETHERTON NOW” campaign to shed light on the profound and poorly understood impacts of Netherton Syndrome. It is estimated that up to 20% of babies born with Netherton Syndrome do not survive, highlighting the urgent need for greater awareness and new treatment options. Currently, Quoin is conducting four ongoing clinical studies evaluating the safety and efficacy of QRX003, in Netherton Syndrome patients. Recently announced clinical data by Quoin has underscored the product’s potential efficacy as a treatment for the disease.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNRX:
- Quoin Pharmaceuticals announces further clinical evidence on QRX003 efficacy
- Quoin announces clinical data from ongoing Pediatric Netherton Syndrome study
- Quoin announces ‘positive’ interim data for Netherton Syndrome studies
- Quoin Pharmaceuticals prices 15.1M ADSs at 45c in public offering
- Quoin Pharmaceuticals announces FDA clearance to initiate QRX003 study